Biodextris invests in a biologics Contract Development and Manufacturing Centre
by CM staff
With the support of the governments of Quebec and Canada and Investissement Québec.
LAVAL — Biodextris Inc., a subsidiary of Clean Biologics SAS, announces the development of a industrial-scale vaccine and biologics development, manufacturing and packaging plant (CDMO). The facility will support companies in the development and characterization of next-generation biological products and will help bridge the gap between research projects and large-scale commercial production.
The project amounts to a $25 million investment in indoor materials and equipment.
“Our company’s biologics development scientist team will be able to support our customers and offer them a range of integrated services and the most advanced technologies, from the initial development phases, through clinical trials, to commercial manufacturing of the product,” said Alain Carrier, General Manager of Biodextris.
Located in Laval’s Biotech City, the team of scientists will occupy an existing 30,000 square feet building that will be custom developed to meet Biodextris’ needs. The centre will include three main spaces: laboratory space dedicated to bioprocess development, analytical laboratories for development, method validation and quality control of manufactured products and finally, five dedicated cGMP biomanufacturing suites. The production service offer will be enhanced by the addition of larger volume bioreactors (50 to 200 liters) and by the addition of an aseptic filling capacity.
This project has received support from the governments of Quebec and Canada and from Investissement Québec. The Quebec government granted a $4 million loan under the ESSOR program, managed by Investissement Québec. Investissement Québec also granted a $1.4 million loan through its own funds. The Government of Canada is supporting the project with a repayable contribution of $1 million, granted under the Regional Economic Growth through Innovation program of Canada Economic Development for Quebec Regions (CED). CED’s assistance will be used to purchase and install biology, biophysics, and medical chemistry equipment. This equipment will enable the SME to become more competitive and continue to grow.
The new biomanufacturing center (cGMP) and its analytical capabilities will be an asset in the development of Biodextris as a world-class CDMO.
“The life sciences sector is a cornerstone of Quebec’s economy, and our expertise is recognized worldwide. Investissement Québec is proud to support Biodextris, a key player in this industry, in its expansion and productivity improvement project,” said Guy LeBlanc, President and CEO of Investissement Québec. “Through our Productivité innovation initiative, the company will acquire new state-of-the-art equipment, which will help bolster Quebec’s expertise in vaccine manufacturing.”
